Allied receives ISO certification for CardioCel
13 February, 2013 by Tim DeanAllied Healthcare (ASX:AHZ) has received ISO 13485 certification for regenerative therapy CardioCel, bringing it a step closer to European CE Mark approval.
Mesoblast boosts R&D spend on stem cell platform
12 February, 2013 by Dylan Bushell-EmblingThe expansion of Mesoblast’s MPC adult stem cell development programs came at a cost in 1H13, but the company has more than adequate cash reserves to cover the increased burn.
MicroRNA found to inhibit spread of melanoma
12 February, 2013 by Tim DeanA study has shown a microRNA being investigated by MiReven can inhibit the spread of metastatic melanoma, reinforcing its prospect as a potential anticancer agent.
Bioniche details plans for Urocidin
11 February, 2013 by Dylan Bushell-EmblingIn a letter to shareholders, Bioniche’s (ASX:BNC) CEO has laid out some plans for the future of bladder cancer treatment Urocidin following its split with former commercialisation partner Endo Pharmaceuticals.
Cellmid options cancer diagnostics tech
11 February, 2013 by Dylan Bushell-EmblingCellmid (ASX:CDY) has secured an option agreement with Japan’s Fujikura covering its midkine cancer diagnostics technology in latex-based tests.
BioDiem testing BDM-I in schistosomiasis
11 February, 2013 by Dylan Bushell-EmblingBioDiem (ASX:BDM) and the QIMR are moving to proof-of-concept testing of BioDiem’s antimicrobial in the parasitic worms that cause the major tropical disease schistosomiasis.
Phosphagenics solves oxycodone patch design problems and plans for new trial
11 February, 2013 by Tim DeanPhosphagenics (ASX:POH) has solved the crystallisation problems with its oxycodone patch and is aiming to re-enter the clinic by the end of this quarter.
Mesoblast up following patents in US and China
07 February, 2013 by Tim DeanMesoblast (ASX:MSB) has made gains on the ASX following an announcement it has secured further patents covering its technology in the US and China.
Free directory listing for Australian biotech and medtech companies
07 February, 2013 by AusBiotechAusBiotech manages two national directories and invites all Australian biotechnology and medical technology companies to list free of charge.
Cynata’s stem cells show promise in treating critical limb ischemia
06 February, 2013 by Tim DeanAn animal trial has shown Cynata’s mesenchymoangioblasts (MCA) cells can help improve blood flow in mice with induced critical limb ischemia.
Allied finds CardioCel better at seeding stem cells
06 February, 2013 by Dylan Bushell-EmblingTests of tissue engineered by Allied Healthcare’s (ASX:AHZ) ADAPT technology support its ability to be used for a “truly regenerative treatment”, according to its CEO.
Metabolic eyes human trials for experimental osteoarthritis treatment
06 February, 2013 by Tim DeanA positive result from an animal trial of Calzada (ASX:CZD) subsidiary Metabolic Pharmaceuticals’ osteoarthritis treatment could lead to phase II human trials beginning soon.
Cochlear record revenue fails to impress investors
06 February, 2013 by Tim DeanCochlear (ASX:COH) has posted record revenue for the second half of 2012, with sales up 27%, although the share price tumbled over 9% following the news.
TGA consults on proposed changes to pre-market assessment for medical devices
05 February, 2013 by AusBiotechThe Therapeutic Goods Administration has proposed changes to the pre-market assessment requirements in its consultation paper released in January.
BioDiem expanding indications for BDM-I
04 February, 2013 by Dylan Bushell-EmblingBioDiem (ASX:BDM) is extending a research agreement with US-based NIAID to cover the evaluation of antimicrobial BDM-I in tuberculosis and serious fungal infections.
